icometrix

About:

icometrix develops automated biomarkers that standardizes MRI scan measurements to improve treatment procedures for neurological disorders.

Website: https://www.icometrix.com/

Twitter/X: icometrix

Top Investors: NHS England, Capricorn Partners, Michael J. Fox Foundation, Optum Ventures, Forestay Capital

Description:

icometrix provides clinicians with standardized measurements on their patients’ brain MRI scans in order to improve personalized care of people with a neurological disorder. icometrix was founded in 2011 by Dirk Loeckx and Wim Van Hecke. It is a spin-off company of the universities and university hospitals of Leuven and Antwerp. Today, icometrix has grown to a team of over 25 people and is internationally active, with headquarters in Leuven and an office in Boston, USA. They are the worldwide standard in MRI biomarkers in routine clinical practice. icometrix developed MSmetrix, which detects brain lesions, calculates lesion volume and measures the whole brain and grey matter volume and atrophy. MSmetrix, received market approval in the EU and other countries including Canada, Brazil and Australia. FDA clearance is pending. Furthermore, icometrix is ISO9001 and ISO13485 (Medical Devices) and ISO27001 (Information Security) certified. icometrix also acts as an image analysis expert in clinical trials and research studies. Imaging biomarkers constantly lead to new insights on neurological disorders. Since recently, imaging biomarker outcomes often serve as the primary endpoints in clinical trials for the development of new drugs. For these purposes large batches of brain imaging data are frequently transferred to icometrix for fast and high quality processing. This way our software-as-a-service is incorporated in clinical trials and large research studies regarding Traumatic Brain Injury (TBI), Epilepsy, Alzheimer’s Disease, Stroke, etc.